中国神经再生研究(英文版) ›› 2015, Vol. 10 ›› Issue (10): 1596-1598.doi: 10.4103/1673-5374.165268

• 观点:脊髓损伤修复保护与再生 • 上一篇    下一篇

靶向急性炎症可促进损伤脊髓修复?

  

  • 收稿日期:2015-07-09 出版日期:2015-10-28 发布日期:2015-10-28
  • 基金资助:

    这项工作得到了澳大利亚脊柱治愈计划(职业发展奖学金),昆士兰大学,国家卫生和澳大利亚医学研究理事会(计划资助1060538)支持

Targeting acute inflammation to complement spinal cord repair

Faith H. Brennan, Marc J. Ruitenberg*   

  1. School of Biomedical Sciences, The University of Queensland, Brisbane, Australia (Brennan FH, Ruitenberg MJ)
    Queensland Brain Institute, The University of Queensland, Brisbane, Australia (Ruitenberg MJ)
    Trauma, Critical Care and Recovery, Brisbane Diamantina Health Partners, Brisbane, Australia (Ruitenberg MJ)
  • Received:2015-07-09 Online:2015-10-28 Published:2015-10-28
  • Contact: Marc J. Ruitenberg, Ph.D.,m.ruitenberg@uq.edu.au.
  • Supported by:

    This work was supported by SpinalCure Australia (Career
    Development Fellowship to MJR), The University of Queensland, and the National Health and Medical Research Council of Australia (Project Grant 1060538 to MJR).

摘要:

免疫效应机制在脊髓损伤中扮演着关键角色。针对SCI的炎症反应包括快速可靠激活先天免疫补体系统,补体成分5A组织水平,即C5a - 一种由补体因子5蛋白水解生成的激活产物(C5),在损伤后12小时和24小时达到峰值。补体系统活化会形成正常宿主防御微生物的前线。然而,在无菌条件下补体激活可以改变病程或疾病结果,包括脊柱损伤。在这样的条件下,大多数研究认为补体活化不利与损伤修复,但最近几年出现的个别报告研究也指出了其积极作用,至少在补体级联中的组织再生和修复方面会有积极效果。在脊髓损伤中研究C5a的作用方面,我们产生了新的想法:这一特定的补体激活产物如何参与SCI的内源性修复过程?具体地说,激活C5a C5AR1初级受体(也称为C5aR或CD88),在急性后期可调节损伤诱导的星形胶质细胞增殖。这些新发现的机制,也突出了如果将C5a-C5AR1轴视为中枢神经系统损伤的治疗靶向时仍有待解决的一些问题。

Abstract:

Immune effector mechanisms play key roles in the progressive (secondary) neurodegenerative changes that follow spinal cord injury (SCI). In our recent paper, we showed that the inflammatory response to SCI includes rapid and robust activation of the innate immune complement system, with tissue levels of complement component 5a (C5a – an activation product that is generated by the proteolysis of complement factor 5 (C5)) peaking between 12 and 24 hours post-injury. Activation of the complement system normally forms the frontline of host defense to microbial challenges. It is now widely recognized, however, that the activation of complement can also modify disease course and/or disease outcomes in sterile inflammatory conditions, including those that affect the nervous system like SCI. Complement activation in such conditions has been mostly thought of as detrimental, but several reports have emerged in recent years also ascribing positive roles to at least some components of the complement cascade in tissue regeneration and repair. In studying the role of C5a in SCI, we generated novel insights regarding how this particular complement activation product is involved in endogenous repair processes. Specifically, we showed that engagement of the primary receptor for C5a, C5aR1 (also known as C5aR or CD88), during the post-acute phase regulates injury-induced astrocyte proliferation. Here, we overview these newly identified mechanisms and also highlight a number of outstanding questions that remain to be addressed when considering the therapeutic targeting of C5a-C5aR1 axis for the treatment of central nervous system (CNS) injury.